Allied achieves GACP certification – A Strategic Milestone in Our International Expansion

Allied Corp is pleased to announce that the company has officially received its CUMCS-GACP certification from Control Union Certifications B.V., in line with the roadmap outlined in our March CEO letter (read here). This is a major achievement that strengthens our ability to supply pharmaceutical-grade medical cannabis to regulated international markets.

WHAT IS GACP ?

CUMCS-GACP certification is a globally recognized standard that demonstrates Allied’s compliance with strict quality and consistency requirements for exporting medical cannabis to Europe, Australia, and other regulated markets. It confirms compliance with:

• World Health Organization (WHO) guidelines on Good Agricultural Practices (GAP) and Good Agricultural and Collection Practices (GACP) for medicinal plants (Geneva, 2003)

• European Medicines Agency (EMA) guidelines on GAP and GACP for herbal medical products

Allied's certification scope includes propagation, cultivation, harvesting, drying, curing, packaging, and storage of Cannabis sativa inflorescences for medicinal use at our facility in Mesa de los Santos, Colombia.

WHY IT MATTERS ?

GACP certification reinforces Allied's pharmaceutical regulatory strategy and positions us to meet growing demand for high-quality medical cannabis:

1. Streamlines supply chain: Allows us to export directly from Colombia to high-value medical markets such as Germany, where GACP is a regulatory import requirement

2. Accelerates commercial execution: Equips us to fulfil GACP-dependent contracts, while opening additional commercial opportunities

3. Strengthens our quality-first foundation: Reinforces Allied's pharmaceutical-grade, quality-first approach as we continue building systems designed to support consistent, compliant growth in regulated markets

This achievement adds to our existing ICA BPA certification and builds on multiple recent successful EU client and auditor inspections, further strengthening Allied’s credibility as a trusted supplier.

LOOKING AHEAD

Europe’s medical cannabis market continues to expand rapidly, with imports in Germany alone surging 457% year-over-year in Q1 2025. With GACP certification secured, Allied is well-positioned to continue to supply its established contracts across Germany, Switzerland, the UK, Australia, and Poland, among others, as outlined in our March CEO letter (read here). In fact, our first two German shipments are expected to land in the coming weeks and months.

“Achieving GACP certification is a testament to the incredible effort and collaboration of the Allied team. I’m proud of what we’ve accomplished as we position Allied to meet rising demand and continue building a pharmaceutical-grade cannabis business through continuous improvement of our quality systems.” — Michael Moses, CEO.

To accelerate this momentum, Allied has opened a financing round [2] to execute on our three core objectives over the next 12-18 months: deliver on US$ 15M signed commercial contracts, capacity expansion and gear up for EU-GMP certification. If you would like to learn more, request access to our teaser deck by clicking on the link here or reach out via email below:

Click here to access teaser

If you’re active in the space or want to exchange on the industry, we welcome the opportunity to connect.

Investor Relations : ir@allied.health

Website : https://www.allied.health

Disclaimer and Forward-Looking Statements:

No regulatory authority assumes responsibility for the accuracy or adequacy of this release.

This press release includes certain statements that may be deemed "forward-looking statements" under U.S. and Canadian securities laws. Forward-looking statements relate to Allied Corp.’s anticipated developments, strategic objectives, performance, and market opportunities. These include, but are not limited to, statements regarding Allied’s growth in Colombia, Kelowna, Nevada, and other key locations; intellectual property filings; joint development and manufacturing initiatives; and planned product introductions.

Forward-looking statements can often be identified by terms such as "anticipates," "believes," "expects," "intends," "plans," "will," "may," and similar expressions. These statements are based on current assumptions, projections, and management’s experience, but are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Notable risks include, but are not limited to, regulatory risks associated with the cannabis industry and market changes ; risks related to competition within the cannabis and medical industries; risks related to potential operational and logistical challenges; risks related to market demand; risks related to economic conditions impacting growth and profitability; risks related to potential delays or adverse changes in project locations or expansion plans; as well as other risks.

Though Allied endeavors to identify important factors that may impact actual outcomes, other unknown factors may also cause results to vary. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

[1] International Cannabis Business Conference.   (May 2025). 

[2] The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.